& Silks, L
Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM, Hameed B, Kowdley KV, McCullough A, Terrault N, Clark JM, Tonascia J, Brunt EM, Kleiner DE, Doo E (2015) Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Regular monitoring and adjustment based on symptoms, urine color, and clinical parameters ensure optimal hydration throughout treatment
Reported and plausible concerns Finally, Nausea, flushing, headache, fatigue, yawning, and appetite changes Consequently, Spontaneous erections and possible priapism For example, Generalized darkening and changes in freckles or existing moles Moreover, Uncertain long-term melanocyte and melanoma-related risk In addition, Unknown cardiovascular, endocrine, reproductive, and drug-interaction effects However, Contamination or dosing variability in unregulated products Current evidence does not prove that Melanotan II directly causes melanoma
[Journal of the American Chemical Society, 2013, vol
R.ChenM.-K.LukkahataiN.HsiaoC.-P.KaushalA.SechrestL.et al (2015)
